The recent results of tolebrutinib in non-active secondary progressive MS presented at the ECTRIMS 2024 conference, reinforce the scientific hypothesis that targeting microglia in nSPMS is a valid ...

Key biomarkers identified can now predict disability progression in multiple sclerosis, offering potential for more ...

A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...

Microglia are a type of small macrophage-like glial cell in the central nervous system. Microglia can engage in phagocytosis, and are involved in immune responses within, as well as the ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...

After hours: September 20 at 7:59 PM EDT Loading Chart for MS ...

A team of researchers has identified critical biomarkers that can predict disability worsening in people with multiple ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening ...

Strategies to mitigate infection risks in MS therapies Go to source). ‘Did you know ... Conversely, patients exhibiting high levels of serum glial fibrillary acidic protein (sGFAP), which reflects ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...